Core dosing concepts for levothyroxine, monitoring intervals, absorption issues, and special clinical populations.
Levothyroxine (LT4) is the standard therapy for hypothyroidism and is typically dosed to normalize TSH in primary hypothyroidism. A common full replacement estimate in healthy adults is approximately 1.6 micrograms per kilogram per day, but dosing must be individualized based on age, cardiac status, pregnancy, and severity of hypothyroidism. Older adults and those with coronary disease generally require lower starting doses with gradual titration to minimize ischemic risk. Because LT4 has a long half-life, steady state is reached in roughly 6 weeks; TSH should be reassessed about 6–8 weeks after a dose change.
Absorption is influenced by timing and co-administered agents. LT4 is best taken on an empty stomach with water, separated from calcium, iron, bile acid sequestrants, and certain foods (soy, high-fiber meals) that reduce bioavailability. Proton pump inhibitors and gastrointestinal disorders can also affect absorption, sometimes necessitating alternative formulations. In central hypothyroidism, TSH is not a reliable monitoring target; free T4 is used instead, typically aiming for mid-to-upper reference range while assessing symptoms.
Pregnancy increases LT4 requirements early; prompt dose adjustment and trimester-specific monitoring reduce adverse outcomes. Over-replacement carries risks, including atrial fibrillation and bone loss, especially in older adults. Under-replacement can contribute to dyslipidemia, fatigue, and cognitive symptoms. A structured approach—appropriate starting dose, consistent administration, follow-up testing at physiologic intervals, and attention to adherence and interactions—optimizes outcomes and reduces unnecessary dose cycling.
Absorption is influenced by timing and co-administered agents. LT4 is best taken on an empty stomach with water, separated from calcium, iron, bile acid sequestrants, and certain foods (soy, high-fiber meals) that reduce bioavailability. Proton pump inhibitors and gastrointestinal disorders can also affect absorption, sometimes necessitating alternative formulations. In central hypothyroidism, TSH is not a reliable monitoring target; free T4 is used instead, typically aiming for mid-to-upper reference range while assessing symptoms.
Pregnancy increases LT4 requirements early; prompt dose adjustment and trimester-specific monitoring reduce adverse outcomes. Over-replacement carries risks, including atrial fibrillation and bone loss, especially in older adults. Under-replacement can contribute to dyslipidemia, fatigue, and cognitive symptoms. A structured approach—appropriate starting dose, consistent administration, follow-up testing at physiologic intervals, and attention to adherence and interactions—optimizes outcomes and reduces unnecessary dose cycling.
Published February 1, 2026